Latest news with #LifecoreBiomedical
Yahoo
29-05-2025
- Business
- Yahoo
Lifecore Biomedical (NASDAQ:LFCR) shareholders have endured a 37% loss from investing in the stock five years ago
While it may not be enough for some shareholders, we think it is good to see the Lifecore Biomedical, Inc. (NASDAQ:LFCR) share price up 20% in a single quarter. But over the last half decade, the stock has not performed well. After all, the share price is down 37% in that time, significantly under-performing the market. With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Given that Lifecore Biomedical didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally hope to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. In the last five years Lifecore Biomedical saw its revenue shrink by 33% per year. That puts it in an unattractive cohort, to put it mildly. It seems pretty reasonable to us that the share price dipped 6% per year in that time. We doubt many shareholders are delighted with this share price performance. It is possible for businesses to bounce back but as Buffett says, 'turnarounds seldom turn'. You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image). You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic. We're pleased to report that Lifecore Biomedical shareholders have received a total shareholder return of 21% over one year. Notably the five-year annualised TSR loss of 6% per year compares very unfavourably with the recent share price performance. This makes us a little wary, but the business might have turned around its fortunes. It's always interesting to track share price performance over the longer term. But to understand Lifecore Biomedical better, we need to consider many other factors. Take risks, for example - Lifecore Biomedical has 3 warning signs (and 1 which shouldn't be ignored) we think you should know about. If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
22-05-2025
- Business
- Yahoo
What Makes Lifecore Biomedical (LFCR) a Beneficiary of the Trade Policies?
Greenhaven Road Capital, an investment management company, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the fund returned around -12% net of fees and expenses, trailing the Russell 2000 by approximately 2% in large part. The Q1 letter focused on President Trump's Liberation Day and the attendant tariff policies rather than company fundamentals. In addition, you can check the fund's top 5 holdings to determine its best picks for 2025. In its first-quarter 2025 investor letter, Greenhaven Road Capital highlighted stocks such as Lifecore Biomedical, Inc. (NASDAQ:LFCR). Lifecore Biomedical, Inc. (NASDAQ:LFCR) is an integrated contract development and manufacturing organization. The one-month return of Lifecore Biomedical, Inc. (NASDAQ:LFCR) was 4.46%, and its shares gained 13.27% of their value over the last 52 weeks. On May 21, 2025, Lifecore Biomedical, Inc. (NASDAQ:LFCR) stock closed at $6.45 per share with a market capitalization of $238.628 million. Greenhaven Road Capital stated the following regarding Lifecore Biomedical, Inc. (NASDAQ:LFCR) in its Q1 2025 investor letter: "In April, shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR), an existing holding and domestic CDMO, sold off with the broader market despite their likely beneficiary status. We took advantage of buying opportunities and took our ownership in the company up to just under 10% of the shares outstanding. As previously discussed, Lifecore is a likely beneficiary of the trade policies. Their largest challenge and opportunity is to sell their excess capacity. As domestic capacity is not sufficient to support significant re-shoring, the new policies increase the likelihood that Lifecore fills out its excess capacity while pulling forward the timing and magnitude of profit margin improvement." A village pharmacist fulfilling a patient's medication prescription in a rural area. Lifecore Biomedical, Inc. (NASDAQ:LFCR) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 10 hedge fund portfolios held Lifecore Biomedical, Inc. (NASDAQ:LFCR) at the end of the fourth quarter compared to 10 in the third quarter. In the fiscal third quarter of fiscal 2025, Lifecore Biomedical, Inc. (NASDAQ:LFCR) generated $35.2 million in revenues compared to $35.7 million for the comparable 2024 period. While we acknowledge the potential of Lifecore Biomedical, Inc. (NASDAQ:LFCR) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In another article, we covered Lifecore Biomedical, Inc. (NASDAQ:LFCR) and shared Greenhaven Road Capital's views on the company in the previous quarter. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
22-05-2025
- Business
- Yahoo
What Makes Lifecore Biomedical (LFCR) a Beneficiary of the Trade Policies?
Greenhaven Road Capital, an investment management company, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the fund returned around -12% net of fees and expenses, trailing the Russell 2000 by approximately 2% in large part. The Q1 letter focused on President Trump's Liberation Day and the attendant tariff policies rather than company fundamentals. In addition, you can check the fund's top 5 holdings to determine its best picks for 2025. In its first-quarter 2025 investor letter, Greenhaven Road Capital highlighted stocks such as Lifecore Biomedical, Inc. (NASDAQ:LFCR). Lifecore Biomedical, Inc. (NASDAQ:LFCR) is an integrated contract development and manufacturing organization. The one-month return of Lifecore Biomedical, Inc. (NASDAQ:LFCR) was 4.46%, and its shares gained 13.27% of their value over the last 52 weeks. On May 21, 2025, Lifecore Biomedical, Inc. (NASDAQ:LFCR) stock closed at $6.45 per share with a market capitalization of $238.628 million. Greenhaven Road Capital stated the following regarding Lifecore Biomedical, Inc. (NASDAQ:LFCR) in its Q1 2025 investor letter: "In April, shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR), an existing holding and domestic CDMO, sold off with the broader market despite their likely beneficiary status. We took advantage of buying opportunities and took our ownership in the company up to just under 10% of the shares outstanding. As previously discussed, Lifecore is a likely beneficiary of the trade policies. Their largest challenge and opportunity is to sell their excess capacity. As domestic capacity is not sufficient to support significant re-shoring, the new policies increase the likelihood that Lifecore fills out its excess capacity while pulling forward the timing and magnitude of profit margin improvement." A village pharmacist fulfilling a patient's medication prescription in a rural area. Lifecore Biomedical, Inc. (NASDAQ:LFCR) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 10 hedge fund portfolios held Lifecore Biomedical, Inc. (NASDAQ:LFCR) at the end of the fourth quarter compared to 10 in the third quarter. In the fiscal third quarter of fiscal 2025, Lifecore Biomedical, Inc. (NASDAQ:LFCR) generated $35.2 million in revenues compared to $35.7 million for the comparable 2024 period. While we acknowledge the potential of Lifecore Biomedical, Inc. (NASDAQ:LFCR) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In another article, we covered Lifecore Biomedical, Inc. (NASDAQ:LFCR) and shared Greenhaven Road Capital's views on the company in the previous quarter. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-04-2025
- Business
- Yahoo
Lifecore Biomedical to Participate at Upcoming CDMO Live 2025 Conference
CHASKA, Minn., April 22, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ('Lifecore'), a fully integrated contract development and manufacturing organization ('CDMO'), today announced that the company will participate in the upcoming CDMO Live 2025 conference. Billed as a premiere partnering event for the biopharma outsourcing industry, CDMO Live will take place May 7-8, 2025, in Rotterdam, Netherlands. During the conference, Jackie Klecker, Lifecore's executive vice president, quality and development services, will chair a discussion featuring external quality leaders from the CDMO industry. The talk will explore approaches for transforming quality management from a potential bottleneck into a strategic driver of CDMO partnerships. Ms. Klecker is well-positioned to lead the discussion based on her more than 30 years of industry experience in quality, manufacturing, and development, including guiding Lifecore's quality assurance for over a decade. Details regarding the discussion are as follows: Quality as a Catalyst: Accelerating CDMO Success Through Quality ManagementChaired by Jackie Klecker, executive vice president, quality and development services, Lifecore BiomedicalWednesday, May 7, 2025, Noon local time in Rotterdam To learn more about the CDMO Live 2025 conference, please visit: About Lifecore Biomedical Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore's website at CONTACT: Lifecore Biomedical, Inc. Contact Information: Vida Strategic Partners Stephanie Diaz (Investors) 415-675-7401 sdiaz@ Tim Brons (Media) 415-675-7402 tbrons@ Ryan D. Lake (CFO) Lifecore Biomedical 952-368-6244 in to access your portfolio
Yahoo
27-03-2025
- Business
- Yahoo
Lifecore Biomedical to Report Financial Results for Third Quarter of Fiscal 2025 on April 3, 2025
Webcast Scheduled for Thursday, April 3 at 4:30 p.m. Eastern CHASKA, Minn., March 27, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ('Lifecore'), a fully integrated contract development and manufacturing organization ('CDMO'), today announced that it will report financial results for the third quarter of fiscal year 2025 on Thursday, April 3, 2025, after market close. At 4:30 p.m. Eastern Time that day, members of Lifecore's senior management team will host a webcast to discuss financial results for the quarter and review recent corporate developments. To listen to the live webcast, or access the archived webcast, please visit the Investor Events & Presentations page of Lifecore's website at: Following the live webcast, an archived version of the webcast will be available on the company's website for 30 days. About Lifecore Biomedical Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore's website at CONTACT: Lifecore Biomedical, Inc. Contact Information: Vida Strategic Partners Stephanie Diaz (Investors) 415-675-7401 sdiaz@ Tim Brons (Media) 415-675-7402 tbrons@ Ryan D. Lake (CFO) Lifecore Biomedical 952-368-6244
